New Delhi, Feb 14: Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organization (CDMO), announced its financial results for the third quarter of FY26, reporting robust growth across key business segments.
Q3 FY26 Performance Highlights:
- Revenue: Rs 1,160 crore, up 14.8% YoY from Rs 1,010 crore in Q3 FY25.
- Adjusted EBITDA: Rs 147 crore, up 21% YoY, with margin expansion to 12.7% from 12.0% last year.
- Adjusted PAT: Rs 86 crore, up 29.5% YoY, with margin improvement to 7.2% from 6.5%.
The CDMO segment drove growth with over 16% revenue increase, supported by double-digit volume expansion. The international branded formulation segment more than doubled sequentially, led by strong demand recovery across key markets. Operational improvements, including better capacity utilization and the ramp-up of new facilities, contributed to EBITDA growth, while tighter overhead control and portfolio rationalization mitigated losses in the API and trade generics segment.
Akums continues its global expansion, recently receiving European Union Good Manufacturing Practice (EU GMP) certification for two manufacturing facilities: renewal for the Oral Solids plant and new certification for the Oral Liquids plant. The company also secured its first UK MHRA approval for Rivaroxaban tablets, reinforcing its presence in regulated markets.
Commenting on the performance, Mr. Sandeep Jain, Managing Director, said:
“The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets.”
Mr. Sanjeev Jain, Managing Director, added:
“Our continued focus on operational excellence and disciplined growth aligns with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide.”
With these strategic milestones, Akums Drugs & Pharmaceuticals Ltd. reinforces its commitment to operational excellence, global expansion, and sustained value creation for stakeholders.